openPR Logo
Press release

Global Alzheimer's Therapeutics Market Set to Reach USD 18.46 Billion by 2029

02-13-2024 07:59 AM CET | Health & Medicine

Press release from: MAXIMIZE MARKET RESEARCH PVT. LTD.

Alzheimer's Therapeutics Market

Alzheimer's Therapeutics Market

Report Highlights:

The Alzheimer's Therapeutics Market size was valued at USD 5.36 Bn. in 2022.
Projected to grow at a CAGR of 19.3% from 2023 to 2029, reaching nearly USD 18.46 Bn.
North America dominated the market in 2021 with a share of about 38%.

For further information or to purchase the full report, please contact:https://www.maximizemarketresearch.com/market-report/alzheimers-therapeutics-market/164747/

Report Scope:

The global Alzheimer's Therapeutics Market is witnessing significant growth, driven by factors such as the increasing prevalence of Alzheimer's disease, advancements in diagnostic technologies, and a large number of drugs in the pipeline. The report covers various segments including Therapeutics, Diagnostics, End-user, and Region.

Research Methodology:

The market research conducted by Maximize Market Research Pvt. Ltd. involved extensive data gathering and analysis, including primary and secondary research methodologies. The data was meticulously analyzed to provide accurate insights into the Alzheimer's Therapeutics Market.

Kindly Click Here for More Information About This Study:https://www.maximizemarketresearch.com/request-sample/164747

Market Drivers:

High Adoption of Biomarkers in Diagnosis and Drug Development: Biomarkers are increasingly utilized in Alzheimer's diagnosis and medication development, driving market growth.
Large Number of Drugs in The Pipeline: The increasing number of drugs in the pipeline for Alzheimer's treatment is expected to propel market growth.
Rising Number of Research Studies: Significant investment in research & development activities and the launch of new products are driving market growth.

Market Restraints:

High Failure Rates of Late-Stage Drugs: The failure of late-stage medications has hampered the global growth of the Alzheimer's therapeutics market.
Segments Covered:

by Therapeutics

1.Cholinesterase Inhibitors
2.NMDA Receptor Antagonist
3.Combination Drug
4.Pipeline Drugs

In terms of therapeutics, the market for Alzheimer's therapies was dominated in 2021 by the cholinesterase inhibitors sector, which had the biggest market share of almost 68%. By the conclusion of the projection period, the segment is predicted to continue growing at a CAGR of roughly 19.2% and to continue to dominate.

Acetylcholinesterase inhibitors, also referred to as cholinesterase inhibitors, are a class of drugs that stop acetylcholine, a neurotransmitter, from breaking down naturally. The enzyme cholinesterase, which breaks down cholinergic neurotransmitters in the body, is suppressed by cholinesterase inhibitors. Because cholinesterase inhibitors have been demonstrated to slightly delay the loss of brain function in people with mild to severe Alzheimer's disease, they are frequently used to treat symptoms related to memory, thinking, language, judgment, and other mental processes.

by Diagnostics

1.Brain Imaging
2.CFS Test for Alzheimer's Disease

by End-user

1.Hospital Pharmacy
2.Retail Pharmacy
3.E-commerce

Kindly Click Here for More Information About This Study:https://www.maximizemarketresearch.com/request-sample/164747

Key Players

1. Bristol-Myers Squibb (United States)
2.Lannett Inc. (Unites States)
3. Corium Inc. (United States)
4. Adamas Pharmaceuticals Inc. (United States)
5. AbbVie Inc. (United States)
6. Biogen Inc. (United States)
7. Johnson & Johnson (United States)
10. Eli Lilly and Company (United States)
11. AstraZeneca PLC (United Kingdom)
12. TauRx Pharmaceuticals Ltd. (United Kingdom)
13. Siemens Healthineers (Germany)
14. Merz Pharma (Germany)
15. Hoffmann-La Roche (Switzerland)
16.Novartis AG (Switzerland)
17. AC Immune (Switzerland)
18. H. Lundbeck A/S (Denmark)
19. Daiichi Sankyo Company, Limited (Japan)
20. Eisai Co. Ltd. (Japan)
21.Zydus Cadila (India)
22. Lupin Limited (india)
23. Aurobindo Pharma Ltd. (India)

Request Sample :https://www.maximizemarketresearch.com/request-sample/164747

Regional Insights:

North America: Dominated the market in 2021 with a share of about 38%, driven by the high prevalence of Alzheimer's disease and significant investment in research & development activities.
Europe, Asia Pacific, Middle East and Africa, South America: Emerging regions with growing demand for Alzheimer's Therapeutics products.
Conclusion: The global Alzheimer's Therapeutics Market is poised for significant growth, driven by increasing prevalence, advancements in diagnostic technologies, and a large number of drugs in the pipeline. However, challenges such as high failure rates of late-stage drugs need to be addressed to unlock the full potential of the market.

Our Trending Reports

Sea Freight Forwarding Market https://www.maximizemarketresearch.com/market-report/sea-freight-forwarding-market/189142/

Sugar Syrup Market https://www.maximizemarketresearch.com/market-report/sugar-syrup-market/189145/

Server Market https://www.maximizemarketresearch.com/market-report/server-market/198992/

Air Treatment Products Market https://www.maximizemarketresearch.com/market-report/air-treatment-products-market/200520/

Kairomones Market https://www.maximizemarketresearch.com/market-report/kairomones-market/200430/

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

sales@maximizemarketresearch.com

+91 96071 95908, +91 9607365656

About Maximize Market Research:

Published by Maximize Market Research, this report serves as a comprehensive guide for industry stakeholders, offering valuable insights into market trends, key players, and growth prospects. With detailed analysis and actionable intelligence, the report aims to empower decision-makers in navigating the evolving landscape of the Radiation Detection, Monitoring, and Safety Market.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Alzheimer's Therapeutics Market Set to Reach USD 18.46 Billion by 2029 here

News-ID: 3382228 • Views:

More Releases from MAXIMIZE MARKET RESEARCH PVT. LTD.

Lab Grown Diamonds Market to Reach USD 57.95 Billion by 2032, Growing at 9.4% CAGR
Lab Grown Diamonds Market to Reach USD 57.95 Billion by 2032, Growing at 9.4% CA …
According to a new report by Maximize Market Research, the global Lab Grown Diamonds Market was valued at USD 28.24 Billion in 2024 and is projected to reach USD 57.95 Billion by 2032, growing at a CAGR of 9.4%. The market expansion is fueled by increasing consumer preference for sustainable, affordable alternatives to natural diamonds and technological innovations in manufacturing. ► Get a sample of the report:https://www.maximizemarketresearch.com/request-sample/193972/ ♦ Key HighlightsaMarket Size: Market Size:
Water Quality Sensor Market to Reach USD 11.29 Billion by 2032, Growing at a 4% CAGR
Water Quality Sensor Market to Reach USD 11.29 Billion by 2032, Growing at a 4% …
According to a new report by Maximize Market Research, the global Water Quality Sensor Market was valued at USD 6.1 Billion in 2024 and is projected to reach USD 11.29 Billion by 2032, growing at a CAGR of 4% during 2025-2032. The market growth is driven by the increasing adoption of smart water monitoring systems, stringent environmental regulations, and demand for real-time water quality assessment across industrial, residential, and governmental
E-House Market to Reach USD 3.05 Billion by 2032, Growing at a CAGR of 7.03% | E-House Market Forecast
E-House Market to Reach USD 3.05 Billion by 2032, Growing at a CAGR of 7.03% | E …
According to a new report by Maximize Market Research, the global E-House Market was valued at USD 1.77 Billion in 2024 and is projected to reach USD 3.05 Billion by 2032, growing at a CAGR of 7.03%. The market growth is driven by the increasing adoption of pre-assembled, modular electrical houses across industrial, renewable energy, and utility sectors worldwide. ► Get a sample of the report:https://www.maximizemarketresearch.com/request-sample/28068/ ♦ Key HighlightsaMarket Size: Market Size: USD
Global Wind Turbine Inspection Services Market to Reach USD 86.22 Billion by 2032, Growing at 11.7% CAGR
Global Wind Turbine Inspection Services Market to Reach USD 86.22 Billion by 203 …
According to a new report by Maximize Market Research, the global Wind Turbine Inspection Services Market was valued at USD 35.58 billion in 2024 and is projected to reach USD 86.22 billion by 2032, growing at a CAGR of 11.7%. The market growth is fueled by increasing wind power capacity installations worldwide and the adoption of advanced inspection technologies, including drones, AI, and robotics. ► Get a sample of the report:https://www.maximizemarketresearch.com/request-sample/77606/ ♦

All 5 Releases


More Releases for Alzheimer

Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928 Key Takeaways • Disease-modifying
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,